COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions - Compare Crush

Research Maatschap Cardiologen Rotterdam Zuid0 sites729 target enrollmentTBD

Overview

Trial is onging in other countries

Registry

who.int

Start Date

TBD

End Date

May 15, 2021

Last Updated

2 years ago

Study Type

Interventional

Sponsor

Research Maatschap Cardiologen Rotterdam Zuid

•\- Consecutive patients with STEMI planned for primary PCI
•\- Deferred written informed consent within 4 hours after initial treatment
•\- Adult men and women aged at least 18 years
•\- Symptoms of acute MI of more than 30 min but less than 6 hours
•\- New persistent ST\-segment elevation \>\= 1 mm in two or more contiguous ECG

•\- Contraindication to prasugrel (e.g., hypersensitivity, active bleeding,
•history of previous intracranial bleed, history of any CVA, including TIA,
•moderate to severe hepatic impairment, GI bleed within the past 6 months, major
•surgery within past 4 weeks)
•\- Patient who has received loading dose of Clopidogrel or ticagrelor for the
•index event or are on chronic treatment of ticagrelor. However, patients on
•maintenance dose clopidogrel for at least 7 days are included in the study. See
•appendix A (patient on clopidogrel maintenance dose)
•\- Oral anticoagulation therapy that cannot be stopped (i.e. patients requiring
•chronic therapy)